STK11 and KEAP1 Mutations as Prognostic Biomarkers in an Observational Real-World Lung Adenocarcinoma Cohort - PubMed

STK11 and KEAP1 Mutations as Prognostic Biomarkers in an Observational Real-World Lung Adenocarcinoma Cohort - PubMed

STK11 and KEAP1 Mutations as Prognostic Biomarkers in an Observational Real-World Lung Adenocarcinoma Cohort

Simon Papillon-Cavanagh 1, Parul Doshi 1, Radu Dobrin 1, Joseph Szustakowski 1, Alice M Walsh 2

Affiliations 

• PMID: 32312757
 
• DOI: 10.1136/esmoopen-2020-000706

Abstract

Introduction: Somatic mutations in STK11 and KEAP1, frequently comutated in non-squamous non-small cell lung cancer (NSQ NSCLC), have been associated with poor response to immune checkpoint blockade (ICB). However, previous reports lack non-ICB controls needed to properly ascertain the predictive nature of those biomarkers. The objective of this study was to evaluate the predictive versus prognostic effect of STK11 or KEAP1 mutations in NSQ NSCLC.

Methods: Patients diagnosed with stage IIIB, IIIC, IVA or IVB NSQ NSCLC from a real-world data cohort from the Flatiron Health Network linked with genetic testing from Foundation Medicine were retrospectively assessed. Real-world, progression-free survival (rwPFS) and overall survival (OS) were calculated from time of initiation of first-line treatment.

Results: We analysed clinical and mutational data for 2276 patients including patients treated with anti-programmed death-1 (PD-1)/anti-programmed death ligand 1 (PD-L1) inhibitors at first line (n=574). Mutations in STK11 or KEAP1 were associated with poor outcomes across multiple therapeutic classes and were not specifically associated with poor outcomes in ICB cohorts. There was no observable interaction between STK11 mutations and anti-PD-1/anti-PD-L1 treatment on rwPFS (HR, 1.05; 95% CI 0.76 to 1.44; p=0.785) or OS (HR, 1.13; 95% CI 0.76 to 1.67; p=0.540). Similarly, there was no observable interaction between KEAP1 mutations and treatment on rwPFS (HR, 0.93; 95% CI 0.67 to 1.28; p=0.653) or OS (HR, 0.98; 95% CI 0.66 to 1.45; p=0.913).

Conclusion: Our results show that STK11-KEAP1 mutations are prognostic, not predictive, biomarkers for anti-PD-1/anti-PD-L1 therapy.

Keywords: KEAP1; STK11; immune checkpoint inhibitor; non-squamous non-small cell lung cancer; prognostic.

© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

Conflict of interest statement

Competing interests: All authors are BMS employees and shareholders. PD is a J&J shareholder, RD is a Merck and J&J shareholder.

Similar articles

• Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.

  Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, Wakelee HA.Lung Cancer. 2019 Jul;133:144-150. doi: 10.1016/j.lungcan.2019.05.015. Epub 2019 May 15.PMID: 31200821
• TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

  Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D.Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15.PMID: 29764856
• NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.

  Xu X, Yang Y, Liu X, Cao N, Zhang P, Zhao S, Chen D, Li L, He Y, Dong X, Wang K, Lin H, Mao N, Liu L.Oncologist. 2020 Apr 9. doi: 10.1634/theoncologist.2019-0885. Online ahead of print.PMID: 32272498
• PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.

  Xia L, Liu Y, Wang Y.Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.PMID: 30819829 Free PMC article. Review.
• The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.

  Takada K, Toyokawa G, Shoji F, Okamoto T, Maehara Y.Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28.PMID: 29153898 Review.